Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Zai Lab Limited - American Depositary Shares (NQ:ZLAB)

32.05 -0.95 (-2.86%)
Streaming Delayed Price Updated: 10:43 AM EDT, May 20, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 130,438
Open 33.00
Bid (Size) 32.00 (2)
Ask (Size) 32.09 (1)
Prev. Close 32.99
Today's Range 31.60 - 33.00
52wk Range 16.01 - 39.77
Shares Outstanding 956,637,360
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Zai Lab Receives U.S. FDA Fast Track Designation for ZL-1310, a DLL3-Targeted Antibody-Drug Conjugate, for Treatment of Extensive-Stage Small Cell Lung Cancer
From Zai Lab Limited
Via Business Wire
Zai Lab Announces First Quarter 2025 Financial Results and Recent Corporate Updates
From Zai Lab Limited
Via Business Wire

Performance

YTD
+29.2%
+29.2%
1 Month
+7.9%
+7.9%
3 Month
+3.6%
+3.6%
6 Month
+27.3%
+27.3%
1 Year
+53.8%
+53.8%

More News

Read More
Earnings Scheduled For May 8, 2025
Via Benzinga
Zai Lab Presents Data Highlighting Potential of Internally Developed, Next-Generation Oncology Therapies at AACR 2025
From Zai Lab Limited
Via Business Wire
Earnings Scheduled For February 27, 2025
Via Benzinga
Zai Lab to Present Data from Phase 1 Trial of DLL3-Targeted Antibody-Drug Conjugate (ADC) ZL-1310 at 2025 ASCO Annual Meeting
From Zai Lab Limited
Via Business Wire
Zai Lab Announces Acceptance of Supplemental New Drug Application for Repotrectinib for Patients with NTRK-Positive Solid Tumors
From Zai Lab Limited
Via Business Wire
Hertz Global And Webull Stocks Are Among Top Mid-Cap Gainers Last Week (Apr 14-Apr 18): Are The Others In Your Portfolio?
Via Benzinga
Zai Lab to Announce First Quarter 2025 Financial Results and Recent Corporate Updates on May 8, 2025
From Zai Lab Limited
Via Business Wire
Fastenal Posts Better-Than-Expected Sales, Joins Simulations Plus, Certara And Other Big Stocks Moving Higher On Friday
Via Benzinga
Why ZAI LAB LTD-ADR (NASDAQ:ZLAB) could fit Mark Minervini’s high-growth criteria
Via Chartmill
No Fear And No Panic After A 10% Correction = No Bottom
Via Talk Markets
Topics Stocks / Equities
Argan Posts Upbeat Results, Joins KULR Technology, Abacus Global Management, W. R. Berkley And Other Big Stocks Moving Higher On Friday
Via Benzinga
Concentrix Posts Better-Than-Expected Earnings, Joins Soleno Therapeutics, Petco Health and Wellness, MillerKnoll And Other Big Stocks Moving Higher On Thursday
Via Benzinga
Zai Lab to Present New Data from Internally Developed, Next-Generation Oncology Candidates at AACR 2025 Annual Meeting
From Zai Lab Limited
Via Business Wire
Zai Lab Announces Acceptance of Biologics License Application for TIVDAK for the Treatment of Patients with Recurrent or Metastatic Cervical Cancer
From Zai Lab Limited
Via Business Wire
Zai Lab Announces Participation in Investor Conferences in March 2025
From Zai Lab Limited
Via Business Wire
NovoCure Q4 EPS Misses, Revenue Matches
Via The Motley Fool
Zai Lab Announces Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Updates
From Zai Lab Limited
Via Business Wire
Watsco Posts Upbeat Results, Joins GeneDx, Intel And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
Zai Lab to Announce Fourth Quarter and Full Year 2024 Financial Results and Provide Recent Corporate Updates on February 27, 2025
From Zai Lab Limited
Via Business Wire
Zai Lab Receives Orphan Drug Designation from the U.S. FDA for ZL-1310 (DLL3 ADC) for the Treatment of Small Cell Lung Cancer (SCLC)
From Zai Lab Limited
Via Business Wire
Zai Lab Announces Acceptance of New Drug Application for KarXT for the Treatment of Schizophrenia
From Zai Lab Limited
Via Business Wire
Zai Lab Announces Positive Topline Results for TIVDAK in the China Subpopulation of the Global Phase 3 innovaTV 301 Trial in Patients with Recurrent or Metastatic Cervical Cancer
From Zai Lab Limited
Via Business Wire
Vertex and Zai Lab Announce Strategic Agreement to Develop and Commercialize Povetacicept in Mainland China, Hong Kong SAR, Macau SAR, Taiwan Region and Singapore
From Vertex Pharmaceuticals Incorporated
Via Business Wire

Frequently Asked Questions

Is Zai Lab Limited - American Depositary Shares publicly traded?
Yes, Zai Lab Limited - American Depositary Shares is publicly traded.
What exchange does Zai Lab Limited - American Depositary Shares trade on?
Zai Lab Limited - American Depositary Shares trades on the Nasdaq Stock Market
What is the ticker symbol for Zai Lab Limited - American Depositary Shares?
The ticker symbol for Zai Lab Limited - American Depositary Shares is ZLAB on the Nasdaq Stock Market
What is the current price of Zai Lab Limited - American Depositary Shares?
The current price of Zai Lab Limited - American Depositary Shares is 32.05
When was Zai Lab Limited - American Depositary Shares last traded?
The last trade of Zai Lab Limited - American Depositary Shares was at 05/20/25 10:43 AM ET
What is the market capitalization of Zai Lab Limited - American Depositary Shares?
The market capitalization of Zai Lab Limited - American Depositary Shares is 30.66B
How many shares of Zai Lab Limited - American Depositary Shares are outstanding?
Zai Lab Limited - American Depositary Shares has 31B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.